Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96853455 | 9685345 | 5 | F | 20120502 | 20140519 | 20131113 | 20160901 | EXP | PHHY2012JP039126 | NOVARTIS | 35.54 | YR | M | Y | 64.00000 | KG | 20160901 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96853455 | 9685345 | 1 | PS | AFINITOR | EVEROLIMUS | 1 | Oral | 10 MG, UNK | 1450 | MG | Y | U | 22334 | 10 | MG | TABLET | QD | ||
| 96853455 | 9685345 | 2 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 5 MG, UNK | 1450 | MG | Y | U | 22334 | 5 | MG | TABLET | QD | ||
| 96853455 | 9685345 | 3 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 10 UNK, UNK | 1450 | MG | Y | U | 22334 | 10 | MG | TABLET | QD | ||
| 96853455 | 9685345 | 4 | SS | AFINITOR | EVEROLIMUS | 1 | 1450 | MG | Y | U | 22334 | TABLET | |||||||
| 96853455 | 9685345 | 5 | C | LENDORMIN | BROTIZOLAM | 1 | Oral | 0.25 MG | U | U | 0 | .25 | MG | ||||||
| 96853455 | 9685345 | 6 | C | PARIET | RABEPRAZOLE SODIUM | 1 | Oral | 20 MG | U | U | 0 | 20 | MG | ||||||
| 96853455 | 9685345 | 7 | C | MIYA-BM | CLOSTRIDIUM BUTYRICUM SPORES STRAIN M-55 | 1 | Oral | 2 DF | U | U | 0 | 2 | DF | ||||||
| 96853455 | 9685345 | 8 | C | BAKTAR | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 1 DF | U | U | 0 | 1 | DF | ||||||
| 96853455 | 9685345 | 9 | C | OXYCONTIN | OXYCODONE HYDROCHLORIDE | 1 | Oral | 80 MG | U | U | 0 | 80 | MG | ||||||
| 96853455 | 9685345 | 10 | C | MAGLAX | MAGNESIUM OXIDE | 1 | Oral | 990 MG | U | U | 0 | 990 | MG | ||||||
| 96853455 | 9685345 | 11 | C | CALONAL | ACETAMINOPHEN | 1 | Oral | 600 MG | U | U | 0 | 600 | MG | ||||||
| 96853455 | 9685345 | 12 | C | METASTRON | STRONTIUM CHLORIDE SR-89 | 1 | UNK UKN, UNK | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 96853455 | 9685345 | 1 | Pancreatic neuroendocrine tumour |
| 96853455 | 9685345 | 2 | Radiotherapy to bone |
| 96853455 | 9685345 | 3 | Radiotherapy to lung |
| 96853455 | 9685345 | 4 | Prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 96853455 | 9685345 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 96853455 | 9685345 | Back pain | |
| 96853455 | 9685345 | Blood albumin decreased | |
| 96853455 | 9685345 | Blood bilirubin increased | |
| 96853455 | 9685345 | Blood glucose increased | |
| 96853455 | 9685345 | Blood phosphorus decreased | |
| 96853455 | 9685345 | Death | |
| 96853455 | 9685345 | Malignant neoplasm progression | |
| 96853455 | 9685345 | Oedema peripheral | |
| 96853455 | 9685345 | Pancreatic neuroendocrine tumour | |
| 96853455 | 9685345 | Platelet count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 96853455 | 9685345 | 1 | 20120418 | 20120503 | 0 | |
| 96853455 | 9685345 | 2 | 20120526 | 20121115 | 0 | |
| 96853455 | 9685345 | 3 | 20121116 | 20121227 | 0 | |
| 96853455 | 9685345 | 12 | 200910 | 0 |